MTSR News
Archived Headlines
- Renaissance Capital's January IPO Market Update 02/03/25
- US IPO Weekly Recap: Active January closes out with several sizable IPOs 01/31/25
- Obesity biotech Metsera offers fewer shares, prices IPO above the range at $18 01/31/25
- Sizable IPO filings reach a three-year high amid steady stream of deals 01/30/25
- Obesity biotech Metsera sets terms for $275 million IPO 01/27/25
See more
LB Pharmaceuticals prepares to break the biotech IPO dry spell
Neuropsych biotech LB Pharmaceuticals (LBRX) filed for a $100 million IPO on Friday, marking the first major new filing from a drug developer since January. Backed by a suite of VCs, LB Pharmaceuticals is initially developing its lead candidate, oral small...read more
Updated: Renaissance Capital's 1Q 2025 US IPO Market Review
IPO Pickup Interrupted by Market Correction In the first quarter of 2025, 53 IPOs raised a combined $8.5 billion, after a strong start was cut off by a market correction near quarter end. Both deal count and proceeds increased from the 1Q24, despite concerns...read more
Bigger Biotechs: IPO valuations have soared for drug developers over the past decade
New biotech issuers have doubled in size over the past decade. Last year, the average biotech IPO went public at a market cap of $644 million, compared to $318 million a decade earlier, for deals raising at least $20 million. The average wasn’t skewed by ...read more
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially. ...read more